Klaas Zuideveld has been appointed chief executive of Versameb AG, a Swiss company developing RNA-based therapeutics. He was previously chief development officer. At the same time, Friedrich Metzger, the company’s co-founder and former CEO, has become chief scientific officer. Versameb is advancing two assets based on its RNA platform from discovery into clinical development.
Dr Zuideveld formerly led pharma partnerships at Caris Life Sciences Inc. Before that he worked at Roche where amongst other things, he led the clinical development of Avastin.
Versamed announced the appointment on 8 January 2021.
Copyright 2021 Evernow Publishing Ltd